Dr. Correo Hofstad

[Cory.hofstad@seattlecolleges.edu](mailto:Cory.hofstad@seattlecolleges.edu)

02/15/2025

Dr. Gabi Chiorean

Hutchinson Cancer Center

Program Head, Phase I Clinical Trials Cover Letter

**Illuminating the Future of Cancer Research: Dr. Correo Hofstad's Visionary Leadership at Fred Hutchinson Cancer Center**

**Introduction: A New Era in Cancer Therapeutics**

In a significant development for cancer research and treatment, Dr. Correo Hofstad is submitting a job application to lead the Phase I Developmental Therapeutics clinical trials program at the Fred Hutchinson Cancer Center (Fred Hutch) with the University of Washington (UW). This exciting opportunity positions Dr. Hofstad, an internationally recognized expert, to head a program that focuses on innovative therapies designed to bring hope and healing to countless cancer patients. With a wealth of experience in hematology and oncology and a passion for pioneering research, Dr. Hofstad is poised to make transformative strides in cancer treatment.

As Program Head, Dr. Hofstad will hold a dual appointment—primary faculty in the Clinical Research Division at Fred Hutch and a secondary appointment in the UW Department of Medicine, Division of Hematology and Oncology. This unique role underscores the collaborative spirit of both institutions, as Dr. Hofstad will work closely with experienced leaders in immunotherapy and cell-based therapy to develop a robust early-phase trial strategy. This transition marks a pivotal moment not only for Dr. Hofstad but also for the broader field of oncology.

**Driving Innovation in Clinical Trials**

Dr. Hofstad's appointment comes as the landscape of cancer treatment rapidly evolves. The Phase I Developmental Therapeutics clinical trials program is critical for translating innovative research into practical, life-saving therapies. Dr. Hofstad will focus on designing, implementing, and managing early-phase clinical trials that test novel therapeutic regimens. By leading these efforts, he will bridge the gap between laboratory discoveries and clinical application, ensuring patients can access cutting-edge treatments as quickly as possible.

An essential element of Dr. Hofstad's strategy will be his collaborative approach. He will partner with leading researchers and clinicians, both at Fred Hutch and UW, to ensure the Phase I program is effective and adaptive to the needs of ongoing research and patient care. This positions Dr. Hofstad to leverage a wealth of resources and expertise to advance developmental therapeutics.

**Setting Standards in Safety and Efficacy**

As the Program Head, Dr. Hofstad will oversee the rigorous evaluation of new treatments, ensuring safety and efficacy for trial participants. His leadership will involve establishing protocols prioritizing patient welfare while pursuing groundbreaking therapies. Dr. Hofstad recognizes that trust and transparency are foundational to adequate clinical trials; thus, he aims to cultivate an environment where patients feel secure and informed throughout their participation.

Moreover, Dr. Hofstad will coordinate the infrastructure required for optimal trial execution. This includes working alongside research nurses, data coordinators, and regulatory affairs teams to streamline the complex processes involved in clinical research. Through effective communication and collaboration, he will enhance the efficiency of trial management, thereby facilitating timely patient accrual—a key determinant of trial success.

**A Commitment to Collaborative Excellence**

Collaboration lies at the heart of Dr. Hofstad's vision. He intends to build a cohesive network that enhances the collective effort toward innovative cancer therapies by fostering strong partnerships with translational researchers and clinical investigators. Such collaborations can catalyze clinical reactions that result in faster development timelines for new treatments, ensuring that the most promising therapeutics reach those most in need.

Additionally, Dr. Hofstad will actively engage with biotech and pharmaceutical companies to expand the capital and resources available to the Phase I program. By establishing these industry relationships, he can grow the program's assets—ultimately increasing the scope and impact of clinical trials under his leadership.

**Leadership Development: Mentorship and Recruitment**

A crucial aspect of Dr. Hofstad's role as Program Head will be to nurture talent and expertise within the Phase I clinical trials program. He will be integral in recruiting and mentoring faculty members who lead these trials. Dr. Hofstad recognizes that any program's strength lies in its people's caliber and dedication.

Dr. Hofstad aims to build a team characterized by excellence, innovation, and a commitment to patient care by emphasizing mentorship. His experience and credibility, bolstered by board certifications in hematology and medical oncology, equip him to guide emerging researchers and clinicians as they navigate the complexities of clinical trials.

**An Academic and Clinical Leader**

Dr. Hofstad will hold a distinguished academic position, with an associate or full professor rank in the Clinical Research Division at Fred Hutch. His dual appointment also includes an associate or full professor status at the UW. Such roles allow Dr. Hofstad to undertake multifaceted academic responsibilities, including research, education, and administrative oversight.

With dedicated time for clinical care, Dr. Hofstad envisages contributing to patient treatment while guiding the scientific inquiry that informs clinical practice. This duality allows him to maintain a keen understanding of patient needs and challenges, which he can then integrate into the research process.

**Transformative Clinical Solutions: The Role of Virus Treatment Centers**

In addition to his responsibilities at Fred Hutch and UW, Dr. Hofstad is also a co-founder of the Virus Treatment Centers (VirusTC). This initiative underscores his commitment to advancing medical science through innovative treatment modalities. VirusTC is on track to open a National Laboratory (VTNL) in 2025, which will broaden access to pioneering therapies and research initiatives.

Dr. Hofstad's involvement in clinical and laboratory settings exemplifies a holistic approach to healthcare, where research directly informs treatment practices. The bridge between his roles promises to invigorate both arenas and offers a framework for developing novel therapeutics that align with contemporary challenges in cancer treatment.

**Pathway to Excellence: Regulatory Framework and Clinical Practice**

As Dr. Hofstad embarks on this new role, he will also navigate the regulatory landscape that governs clinical trials. Ensuring compliance with all necessary guidelines is crucial for the integrity of clinical research. His comprehensive knowledge gained through the United States Medical Licensing Examination (USMLE) and the Comprehensive Osteopathic Medical Licensing Examination of the United States (COMLEX-USA) positions him as a competent steward of regulatory compliance.

Effective clinical trial implementation also requires engaging with community oncology providers. By reaching out to these providers, Dr. Hofstad will enhance patients' access to Phase I trials, particularly those in underserved communities. His commitment to equitable access underscores a compassionate approach to patient care that is integral to Fred Hutch's mission.

**A Vision for the Future: Advancing Cancer Therapies**

Dr. Hofstad's extensive background and innovative mindset will be cornerstones for advancing the Phase I Developmental Therapeutics clinical trials program. His array of accomplishments includes FDA-approved breakthroughs in cancer treatment, signifying his role as a trailblazer in the field. By leveraging technologies such as UV-C light in surgical applications and plant-based synthetic blood components, Dr. Hofstad is reshaping cancer treatment paradigms.

Furthermore, Dr. Hofstad's history of substantial research, evidenced by a robust publishing record and NIH grant funding, conveys his dedication to scientific inquiry. This commitment ensures that he remains at the forefront of advancements in cancer therapeutics, underpinning the integrity of the work conducted under his leadership.

**A Future Filled with Hope**

As Dr. Correo Hofstad submits his job application to lead the Phase I Developmental Therapeutics clinical trials program at Fred Hutch and UW, the oncology community feels a palpable sense of anticipation. His visionary approach and proven track record promise to usher in a new era of innovative therapies that can dramatically improve patient outcomes.

Dr. Hofstad's journey exemplifies a blend of scientific excellence, compassionate patient care, and an unwavering commitment to advancing cancer research. By leading this program, he encapsulates Fred Hutch's mission to discover new cures and make life beyond cancer a reality for countless individuals and families affected by this disease.

In a world grappling with the complexities of cancer treatment, Dr. Hofstad embodies a beacon of hope—a leader ready to shape the future of oncology through collaboration, innovation, and an unyielding dedication to patient welfare.

A black scribble on a white background

AI-generated content may be incorrect.**Dr. Correo “Cory” Andrew Hofstad Med Sci. Educ, PO, ND, DO, PharmD**, **OEM, GPM, Psych**, **MD, JSD, JD, SEP, MPH, PhD, MBA/COGS, MLSCM**, **MDiv**